BillionToOne, Inc. - Class A common stock (BLLN)
90.84
-0.70 (-0.76%)
NASDAQ · Last Trade: Nov 19th, 3:50 PM EST
Lost Money on BillionToOne, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 6.32% Share Price Drop
Investors who lost money on BillionToOne, Inc. ("BillionToOne" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of BillionToOne, Inc. (NASDAQ: BLLN) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 18, 2026 disclosure regarding BillionToOne, Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 19, 2026
Did You Lose Money on BillionToOne, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 6.32% Share Price Decline
Investors who suffered losses on BillionToOne, Inc. ("BillionToOne" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of BillionToOne, Inc. (NASDAQ: BLLN) investors into whether the Company may have violated the federal securities laws. The investigation comes after a November 18, 2026 disclosure concerning BillionToOne, Inc.
By The Law Offices of Howard G. Smith · Via Business Wire · November 19, 2026
Lost Money in BillionToOne, Inc. (NASDAQ: BLLN)? Gibbs Mura is Investigating Potential Securities Law Violations on Behalf of BLLN Investors
Shares of BillionToOne, Inc. (“BillionToOne”) fell over 6% on November 18, 2026, after Fuzzy Panda Research published a report alleging that the company is the subject of an undisclosed state Medicaid fraud investigation and has engaged in improper billing practices. Gibbs Mura is investigating a potential BillionToOne (NASDAQ: BLLN) Securities Class Action Lawsuit concerning whether BillionToOne has violated federal securities laws by providing false or misleading statements to investors.
By Gibbs Mura · Via Business Wire · November 18, 2026
Lost Money on BillionToOne, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 6.32% Stock Decline
BillionToOne, Inc. ("BillionToOne" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in BillionToOne, Inc. (NASDAQ: BLLN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about BillionToOne, Inc. on November 18, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · November 18, 2026
BillionToOne Responds to Inaccurate and Misleading Short Seller Report
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company today responded to a report published on November 18, 2026 by Fuzzy Panda Research, a short seller that, by its own disclosure, holds a short position in BillionToOne securities and stands to profit from driving down the company’s stock price.
By BillionToOne, Inc. · Via GlobeNewswire · November 18, 2026
Rosen Law Firm Encourages BillionToOne, Inc. Investors to Inquire About Securities Class Action Investigation - BLLN
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BillionToOne, Inc. (NASDAQ: BLLN) resulting from allegations that BillionToOne may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · November 18, 2026
BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
By BillionToOne, Inc. · Via GlobeNewswire · November 18, 2026
BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.
By BillionToOne, Inc. · Via GlobeNewswire · November 4, 2026
BillionToOne to Participate in Two Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.
By BillionToOne, Inc. · Via GlobeNewswire · October 27, 2026
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · October 14, 2026
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
By BillionToOne, Inc. · Via GlobeNewswire · October 7, 2026
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.
By BillionToOne, Inc. · Via GlobeNewswire · August 5, 2026
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · July 15, 2026
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.
By BillionToOne, Inc. · Via GlobeNewswire · May 27, 2026
BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.
By BillionToOne, Inc. · Via GlobeNewswire · May 6, 2026
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, May 6, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · April 15, 2026
BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026.
By BillionToOne, Inc. · Via GlobeNewswire · March 4, 2026
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · February 17, 2026
BillionToOne Provides Guidance for 2026
MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.
By BillionToOne, Inc. · Via GlobeNewswire · January 12, 2026
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference.
By BillionToOne, Inc. · Via GlobeNewswire · December 23, 2025
BillionToOne Reports Third Quarter 2025 Results
MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025.
By BillionToOne, Inc. · Via GlobeNewswire · December 9, 2025
BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · December 2, 2025
BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 682,665 shares of Class A common stock at a public offering price of $60.00 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by BillionToOne, were approximately $314.0 million. BillionToOne’s Class A common stock began trading on the Nasdaq Global Select Market on November 6, 2025, under the ticker symbol “BLLN.”
By BillionToOne, Inc. · Via GlobeNewswire · November 7, 2025